Home | Business News | Browse by Publication | M | Medical Letter on the CDC & FDA

Study data from University of the Pacific update understanding of hip replacements.

Publication: Medical Letter on the CDC & FDA
Publication Date: 04-OCT-09
Format: Online
Delivery: Immediate Online Access

Article Excerpt
According to a study from the United States, "Rivaroxaban is a highly potent direct factor Xa inhibitor with competitive and reversible activity that is pending FDA approval for the indication of venous thromboembolism (VTE) prophylaxis in patients undergoing total knee replacement (TKR) or total hip replacement (THR) surgery. Unlike...



More articles from Medical Letter on the CDC & FDA
New hypertension data have been reported by scientists at University o..., October 04, 2009
Reports from University of California advance knowledge in multiple sc..., October 04, 2009
Study results from Hogan & Hartson, LLP broaden understanding of oncol..., October 04, 2009
Research from N. Yoshii and co-researchers in the area of Escherichia ..., October 04, 2009
Accellion Introduces Secure File Transfer for Multifunction Devices an..., October 04, 2009

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.